Clinical Trial Update: Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder [Phase 1, Phase 2]

View source ↗

Summary

Clinical trials evaluating SRX246 in adults with intermittent explosive disorder have completed (Phase 1/2) with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Explosive Disorder

Drugs mentioned

• SRX246

Snippet

Sponsor: Azevan Pharmaceuticals | Conditions: Intermittent Explosive Disorder | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-10-29